Monthly Archives - March 2023

Wasabi CFO On Doing Business With SVB: What Worked, What Didn’t And What’s Ahead

Silicon Valley Bank: The Right Bank, But Wasabi Ready To Move On. The surprise demise of Silicon Valley Bank (SVB) has left much of the tech startup business concerned. Those clients primarily were tech startups that depended on SVB for loans, virtual currency business and financing acquisitions. One of those SVB companies was Boston-based cloud storage technology developer Wasabi, which had banked with SVB for years. Wasabi was fortunate in that it was already making plans to take advantage of...
Read more...

Myomo Reports Fourth Quarter and Full Year 2022 Financial Result

Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and full year ended December, 31, 2022. inancial and operational highlights for the fourth quarter of 2022 include the following: Product and total revenues were $4.0 million, up 2% sequentially and similar to the prior year quarter; Revenue units were 101, up 16% sequentially and down 6% compared with the prior year...
Read more...

Akston Biosciences Ends Vaccine Partnership with Stelis, Continues to Advance COVID Universal Booster EUA

Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today it has ended its AKS-452 licensing, manufacturing, and commercialization agreement with Stelis Biopharma Limited, an arm of Strides Pharma Science Ltd. Akston has reclaimed all rights to AKS-452, a room temperature stable, low-cost, protein subunit COVID-19 vaccine. AKS-452 has completed a Phase II/III clinical trial in India, with data showing robust safety profile and a 91% seroconversion rate at Day 56. Akston is now working with a...
Read more...

Candidly picks up student debt relief where new US policies leave off

While some fintech companies have taken the borrower approach, others are looking at it from an employee benefit perspective and attracting interest from venture capital investors. Those include Goodly, Highway Benefits, which announced $3.1 million in seed funding last week, and Candidly, which announced $20.5 million in Series B funding today. Read more >>
Read more...

Candidly Raises $20.5 Million to Help Millions of Americans Repay Student Debt and Build Savings

Candidly, the market’s most comprehensive student debt and savings optimization platform, today announced it raised $20.5M in a Series B round of financing, led by Altos Ventures, with follow-on participation from Cercano Management. The Series B financing follows a year of record growth in which the company saw 10x revenue growth and a 3,600% increase of payments flowing through the Candidly platform. Read more >>
Read more...

What Will The Future Hold For Celebrity Endorsements In The Wine Industry

While celebrity endorsements and entertainment value remain most relevant in the wine industry, the company is forging a new avenue for brands, retailers, and consumers to pursue. Whilst endorsements still happen brands are more so than ever looking to expand their relationship with talent to make it more authentic. Canned wine company Archer Roose, founded by Marian Leitner-Waldman and started in 2014, is a prime example of this through its partnership with Cocaine Bear star Elizabeth Banks. Banks has been...
Read more...

OmniLife Health Survey Shows Rapid Adoption of Clinical Workflow Automation Among U.S. Healthcare Organizations

Healthcare organizations nationwide are increasing their use of clinical workflow automation (CWA) software to enhance productivity, reduce costs and improve patient outcomes, particularly in complex care environments. This is one of several key learnings from a recent Becker’s Healthcare benchmark survey of health systems, hospitals and transplant centers in partnership with OmniLife Health in late 2022.
Read more...

Xylyx Bio launches new website to showcase growing portfolio of regenerative biotechnologies

Xylyx Bio, a New York-based regenerative medicine company leading the development of advanced biomaterials and biosystems, is proud to announce the launch of their redesigned website showcasing the company's growing portfolio of regenerative biotechnologies. Leveraging its core expertise in bioengineering, Xylyx Bio has expanded its developmental pipeline beyond advanced biomaterials for disease modeling and drug testing to include novel breakthrough technologies for tissue and organ regeneration. Read more >>
Read more...